Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus

NEXT STORY
A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
PREV STORY
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

author_avatar
NASDAQ Market News

Protech Home Medical Releases Third Quarter Financial Results

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ...

author_avatar
NASDAQ Market News

Global Native Bacterial and Viral Antigens Market Forecast to 2027 – A Predicted CAGR of 6.8% from 2020 to 2027

author_avatar
NASDAQ Market News